As measured annually during the study period, mean LDL levels of patients who received aggressive treatment ranged from 93 to 97 mg/dL compared with 132 to 136 mg/ dL for patients who received moderate treatment (P<0.001). Angiography 4 years after study initiation demonstrated that aggressive cholesterol reduction lowered the incidence of new vein graft occlusions (10% versus 21%, aggressive reduction versus moderate reduction; P<0.0001) and the number of grafts with progression of atherosclerosis (27% versus 39%, aggressive reduction versus moderate reduction; P<0.001).68 In a follow-up study of trial participants 3 years later, the aggressive treatment approach was associated with a 30% reduction in the need for repeat revascularization and a 24% reduction in adverse cardiovascular events (both P=0.001).87 Overall, the Post-CABG trial noted that aggressive lowering of LDL to <100 mg/dL reduced both cardiovascular events and the progression of atherosclerosis in native coronary arter- ies and saphenous vein grafts.68,87 The importance of postoperative LDL reduction with statins has been confirmed in several other randomized and observational studies in the cardiac surgery literature. 